Novartis has opened a new 10,000ft² radioligand therapy (RLT) manufacturing facility in Carlsbad, California, as part of a $23bn investment in the US by 2030. The site increases capacity and strengthens supply chain capabilities for RLTs in the country, aiming to minimize damage to surrounding cells with precision medicine. Novartis plans to establish more RLT manufacturing sites across the US, with a total investment of close to $50bn in its US operations over five years, solidifying its commitment to healthcare infrastructure in the country.

Read more at Yahoo Finance: Novartis opens California site for RLT manufacturing